<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> and <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> are two well-reported risk factors for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of the synergistic combination of these two factors on vascular function need to be investigated </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Four groups of male mice were used: a control <z:mp ids='MP_0002169'>wild-type</z:mp> group; a group of mice heterozygous for <z:chebi fb="0" ids="17755">cystathionine</z:chebi> beta-synthase deficiency; a group of mice heterozygous for <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-I deficiency; and, finally, a group of double heterozygous mice, with both <z:chebi fb="0" ids="17755">cystathionine</z:chebi> beta-synthase and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-I deficiency </plain></SENT>
<SENT sid="3" pm="."><plain>To characterize the resulting phenotype, several parameters including plasma <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles, <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, blood pressure and aortic protein were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>As expected, our results indicate that double heterozygous mice are a model of mild <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> and <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Further, the additive combination of both risk factors resulted in a significant increase in blood pressure compared with control animals (136 +/- 8.0 versus 126 +/- 7.5 mm Hg, P &lt; 0.01) that was not present in single heterozygous mice </plain></SENT>
<SENT sid="6" pm="."><plain>The increase in blood pressure was associated with decreased plasma nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> levels, <z:mp ids='MP_0002625'>left ventricle hypertrophy</z:mp> and was independent of <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) cholesterol, para-oxonase activity and kidney histological changes </plain></SENT>
<SENT sid="7" pm="."><plain>Concomitant decreases in levels of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-IV (APOA-IV) and caveolin-1 content were also found in the double heterozygous group </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our findings suggest an additive adverse effect of <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> and <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> on endothelial function to generate clinical <z:hpo ids='HP_0000822'>hypertension</z:hpo> and cardiac <z:hpo ids='HP_0003712'>muscle hypertrophy</z:hpo> mediated by dysregulation in nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> metabolism </plain></SENT>
</text></document>